Antibodies capable of specifically binding TL1a and use thereof

Abstract

The present disclosure relates to antibodies that specifically binding to TL1A and uses thereof, in particular to antibodies that specifically bind to TL1A or antigen- binding fragments thereof, nucleic acids encoding the antibodies or antigen-binding fragments thereof, vectors containing the nucleic acids, and host cells containing the nucleic acids or the vectors. Pharmaceutical compositions comprising the antibodies as well as methods of treatment using the antibodies are also provided.